GreenCentre Partners with Chiral Technologies to Commercialize a New Catalyst for Fine Chemical Synthesis
GreenCentre Canada and Chiral Technologies Inc. are pleased to announce an agreement to jointly commercialize a powerful new catalyst technology for synthesis of fine chemicals, including pharmaceuticals and fragrance products.
Under this agreement, GreenCentre and Chiral Technologies will jointly introduce this new technology to a wide array of potential customers, assess the market interest, and develop a marketing and sales plan to grow this product line to a commercial success.
“GreenCentre is very pleased to partner with an international leader in enantioselective chromatography offering a wide range of chiral stationary phases and columns,” said Pete Pigott, Executive Director of GreenCentre Canada. “Chiral Technologies’ established distribution channels into the pharmaceutical industry are truly global in nature and will allow GreenCentre unprecedented access to these markets.”
The fine chemical industry relies on specialized metal-based catalysts that are highly selective and versatile. However, the use of these catalysts often result in excess waste and a lack of catalyst re-usability. More industrially attractive is the use of “flow” reaction systems in which the catalyst is physically attached to a solid support.
To address this challenge, GreenCentre has been commercializing a technology that allows complex metal-based homogeneous catalysts to be effectively used in flow reactor systems. Originally invented by Professor Steve Bergens at the University of Alberta, the system allows expensive, metal-based catalysts to be attached for use in flow reactor systems. Recent results from industrially sponsored projects have demonstrated an unprecedented level of catalyst activity and re-use, making the technology highly attractive for the manufacture of pharmaceutical compounds.
“Chiral Technologies is excited to be involved in this collaboration with GreenCentre Canada and the University of Alberta. This technology has the potential to make a profound change in our customers’ approach to selective catalysis,” said Joe Barendt, President of Chiral Technologies.
About Chiral Technologies
Chiral Technologies, a wholly owned subsidiary of Daicel Corporation, is the global leader in enantioselective chromatography, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers. In addition, the company also supplies bulk chiral stationary phases and operates an outsourcing centre for separation of chiral intermediates and APIs in pre-clinical and clinical evaluations. For more information, visit www.chiraltech.com.
GreenCentre Canada – Leah Carter, email@example.com
Chiral Technologies Inc. – Stephanie Kuhla, firstname.lastname@example.org